Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use FAMCICLOVIR TABLETS safely and effectively. See full prescribing information for FAMCICLOVIR TABLETS. FAMCICLOVIR tablets, for oral use Initial U.S. Approval: 1994
Medication labelWhy this: Advisory · dailymed-prescription
Herpes labialis(cold sores): Famciclovir is indicated for the treatment of recurrent herpes labialis in adult patients. Genital herpes: Recurrent episodes: Famciclovir is indicated for the treatment of recurrent episodes of genital herpes. The efficacy of famciclovir when initiated more than 6 hours after onset of symptoms or lesions has not been established. Suppressive therapy: Famciclovir is indicated for chronic suppressive therapy of recurrent episodes of genital herpes in adult patients. The efficacy and safety of famciclovir for the suppression of recurrent genital herpes beyond 1 year have not been established. Herpes zoster (shingles): Famciclovir is indicated for the treatment of herpes zoster in adult patients. The efficacy of famciclovir when initiated more than 72 hours after onset of rash has not been established. Recurrent orolabial or genital herpes: Famciclovir, USP is indicated for the treatment of recurrent episodes of orolabial or genital herpes in HIV-infected adults. The efficacy of famciclovir, USP when initiated more than 48 hours after onset of symptoms or lesions has not been established. Limitation of Use The efficacy and safety of famciclovir have not been established for: • Patients with first episode of genital herpes • Patients with ophthalmic zoster • Immunocompromised patients other than for the treatment of recurrent orolabial or genital herpes in HIV-infected patients • Black and African American patients with recurrent genital herpes
- generic_name
- famciclovir
- product_names
- Famciclovir
- ndc
- 71205-609, 33342-026, 71205-609-21, 71205-609-30, 71205-609-60, 71205-609-90
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en